secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amphastar Pharmaceuticals, Inc. (AMPH)
CIK:        0001297184
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001297184-25-000003
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amphastar Q4 net revenue $186.5M, adj EPS $0.92; FY $732M, adj EPS $3.86
------------------------------------------------------------------------

- Q4 net revenue $186.5M, up 4.7% YoY; GAAP net income $38.0M ($0.74 per share).
- FY 2024 net revenue $732.0M, up 13.6% YoY; GAAP net income $159.5M ($3.06 per share).
- Adjusted non-GAAP net income Q4 $47.2M ($0.92 per share); FY $200.8M ($3.86 per share).
- Primatene MIST exceeded $100M annual sales in 2024; BAQSIMI factory sales grew 12% vs Q4 2023.
- CEO cites progress on proprietary pipeline for 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000003/0001297184-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1297184/000129718425000003/amph-20250227x8k.htm
  HTML page:      https://secwatch.observer/filing/0001297184-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer